Product Description
GSK was developing this histamine H3 receptor antagonist for the treatment of Alzheimer's, schizophrenia, and multiple sclerosis.ÊThe rationale was to boost release in the brain of histamine, acetylcholine, noradrenaline, and dopamine in an attempt to enhance cognitive processes. (Sourced from: https://www.alzforum.org/therapeutics/gsk239512)
Mechanisms of Action: H3 Antagonist,H3 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Sclerosis, Relapsing-Remitting|Alzheimer Disease|Schizophrenia|Multiple Sclerosis
Phase 1: Alzheimer Disease|Multiple Sclerosis|Dementia|Cognitive Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01802931 | P1 |
Completed |
Multiple Sclerosis |
2013-04-15 |
2019-03-19 |
Treatments |
|
| H3B109689 | P1 |
Completed |
Alzheimer Disease |
2009-06-16 |
2019-03-18 |
Treatments |
|
| H3B106026 | P1 |
Completed |
Cognitive Dysfunction|Dementia |
2008-03-01 |
2019-03-21 |
Treatments |
|
| 2012-003627-38 | P2 |
Completed |
Multiple Sclerosis |
2014-09-12 |
2022-03-13 |
Treatments |
|
| NCT01772199 | P2 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2014-09-01 |
2019-03-19 |
Treatments |
|
| NCT01009060 | P2 |
Completed |
Schizophrenia |
2011-08-10 |
2019-03-19 |
Treatments |
|
| NCT01009255 | P2 |
Completed |
Alzheimer Disease |
2010-11-10 |
2019-03-19 |
Treatments |
|
| 2009-012614-48 | P2 |
Completed |
Alzheimer Disease |
2010-11-08 |
2022-03-13 |
Treatments |
|
| 2007-004117-33 | P2 |
Terminated |
Alzheimer Disease |
2009-06-16 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/01/2021 |
PubMed |
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. |
|
02/01/2020 |
PubMed |
Tau overexpression exacerbates neuropathology after repeated mild head impacts in male mice. |